AETERNA ZENTARIS INC. Common Shares At Market Issuance Sales Agreement
Exhibit 99.2
Common Shares
At Market Issuance Sales Agreement
June
29, 2011
XxXxxxxx, Xxxxx & Vlak LLC
1251 Avenue of the Xxxxxxxx
00xx Xxxxx
Xxx Xxxx, Xxx Xxxx 00000
1251 Avenue of the Xxxxxxxx
00xx Xxxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Aeterna Zentaris Inc. (the “Company”), a corporation formed under the Canada Business
Corporations Act (the “CBCA”), confirms its agreement (this “Agreement”) with
XxXxxxxx, Xxxxx & Vlak LLC (“MLV”), as follows:
1. Issuance and Sale of Shares.
(a) The Company agrees that, from time to time during the term of this Agreement, on the terms
and subject to the conditions set forth herein, it may issue and sell through MLV, common shares
(the “Placement Shares”) of the Company (the “Common Shares”), provided, however,
that in no event shall the Company issue or sell through MLV such number of Placement Shares (a)
that exceeds the amount authorized by the Board of Directors of the Company from time to time to be
issued and sold under this Agreement or (b) for which the aggregate offering price exceeds the
aggregate dollar amount of Common Shares registered on the Registration Statement (as defined
below) pursuant to which the offering is being made (taking into account all current and future
prospectus supplements filed with respect to the Registration Statement and any post-effective
amendments thereto); provided, however that with respect to “at-the-market” distributions of
Placement Shares, the market value of the Placement Shares distributed under any single Prospectus
Supplement (defined below) shall not exceed 10% of the aggregate market value of the Company’s
outstanding Common Shares as of the date specified in Section 9.1 of National Instrument
44-102—Shelf Distributions (“NI 44-102”), which shall be calculated in accordance with Section 9.2
of NI 44-102 (the “Maximum Amount”). Notwithstanding anything to the contrary contained
herein, the parties hereto agree that compliance with the limitations set forth in this Section
1 and Part 9 of NI 44-102 on the amount of Placement Shares issued and sold under this
Agreement shall be the sole responsibility of the Company and that MLV shall have no obligation in
connection with such compliance. The issuance and sale of Placement Shares through MLV will be
effected pursuant to the Registration Statement (as defined below) filed by the Company and
declared effective by the Securities and Exchange Commission (the “Commission”), although
nothing in this Agreement shall be construed as requiring the Company to use the Registration
Statement to issue Common Shares.
(b) Short Form Prospectus. The Company has prepared and filed with the Québec Autorité des
marchés financiers (the “AMF”) and the other Canadian provincial securities regulatory
authorities (the AMF and such other regulatory authorities, collectively, the “Canadian
Commissions”), a final short form base shelf prospectus dated July 15, 2010 (“Canadian Base
Prospectus”) relating to the offering of up to an aggregate $85,000,000 of Common Shares and
warrants or any combination thereof (together with any documents incorporated therein by reference,
and any supplements or amendments thereto (the “Canadian Base Prospectus”) in accordance
with the Securities Act (Quebec) and the rules, regulations and orders made thereunder
(collectively, the “Canadian Securities Laws”). The Company has prepared the Canadian Base
Prospectus pursuant to National Instrument 44-101—Short Form Prospectus Distributions and NI
44-102 (together, the “Shelf Procedures”). The Company has obtained from the AMF a receipt
for the Canadian Base Prospectus (a “Final Receipt”).
(c) U.S. Base Prospectus. The Company has prepared and filed with the U.S. Securities and
Exchange Commission (the “Commission”) pursuant to the Canada/U.S. Multi-Jurisdictional
Disclosure System adopted by the Canadian Commissions and the Commission (the “MJDS”), a
registration statement on Form F-10 (Registration No. 333-167915) registering the offering and sale
of Common Shares and warrants or any combination thereof under the U.S. Securities Act of 1933, as
amended (together with the rules and regulations thereunder, the “Securities Act”),
including the Canadian Base Prospectus (together with any documents incorporated therein by
reference, any supplements or amendments thereto and with such deletions therefrom and additions or
changes thereto as are permitted or required by Form F-10 and the applicable rules and regulations
of the Commission (the “Rules and Regulations”)) (the “U.S. Base Prospectus”). The
Canadian Base Prospectus and the U.S. Base Prospectus are hereinafter collectively sometimes
referred to as the “Base Prospectuses.”
(d) Prospectus Supplements. The Company will file (i) with the AMF, in accordance with the
Shelf Procedures, a prospectus supplement setting forth the Shelf Information (as defined below)
(including any documents incorporated therein by reference and any supplements or amendments
thereto, the “Canadian Prospectus Supplement”), and (ii) with the Commission, the Canadian
Prospectus Supplement (with such deletions therefrom and additions or changes thereto as are
permitted or required by Form F-10 and the applicable Rules and Regulations, the “U.S.
Prospectus Supplement”). The information, if any, included in the Canadian Supplement that is
omitted from the Canadian Prospectus for which a Final Receipt has been obtained from the AMF, but
that is deemed under the Shelf Procedures to be incorporated by reference into the Canadian
Prospectus as of each Applicable Time, is referred to herein as the “Shelf Information.”
The U.S. Prospectus Supplement and the Canadian Supplement are hereinafter collectively sometimes
referred to as the “Prospectus Supplements.”
(e) Registration Statement. The registration statement on Form F-10, including the exhibits
thereto and the documents incorporated by reference therein and including the U.S. Prospectus (as
defined below), as amended or supplemented in connection with the execution and delivery of this
Agreement, is herein called the “Registration Statement.” Any reference to any amendment
or supplement to the Registration Statement or the U.S. Prospectus shall be deemed to refer to and
include any documents filed with the AMF and the Commission after the effectiveness of such
Registration Statement or the date of such U.S. Prospectus and prior to the termination of this
offering and which are incorporated by reference in such
2
Registration Statement or U.S. Prospectus. The term “Canadian Prospectus” shall refer
to the Canadian Base Prospectus, as supplemented by any Canadian Prospectus Supplement relating to
the Placement Shares, including, in each case, the documents incorporated by reference therein.
The term “U.S. Prospectus” shall refer to the U.S. Base Prospectus, as supplemented by any
U.S. Prospectus Supplement relating to the Placement Shares, including, in each case, the documents
incorporated by reference therein. Any amendment to the Canadian Prospectus, and any amended or
supplemented prospectus or auxiliary material, information, evidence, return, report, application,
statement or document that may be filed by or on behalf of the Company under Canadian Securities
Laws prior to the termination of this offering or, any such document deemed to be incorporated by
reference into the Canadian Prospectus, prior to the termination of this offering, is referred to
herein collectively as the “Supplementary Material.” The U.S. Prospectus and the Canadian
Prospectus are hereinafter collectively sometimes referred to as the “Prospectuses.” Any
reference herein to the Registration Statement, the Prospectus or any amendment or supplement
thereto shall be deemed to refer to and include the documents incorporated by reference therein,
and any reference therein to the terms “amend,” “amendment” or “supplement” with respect to the
Registration Statement or the Prospectus shall be deemed to refer to and include the filing after
the execution hereof of any document with the Commission deemed to be incorporated by reference
therein (the “Incorporated Documents”). For purposes of this Agreement, all references to
the Registration Statement, the U.S. Prospectus or to any amendment or supplement thereto shall be
deemed to include any copy filed with the Commission pursuant to its Electronic Data Gathering
Analysis and Retrieval System (“XXXXX”).
Each of the Company and MLV hereby agrees and acknowledges that all sales and solicitations of
sales of Common Shares by MLV as agent of the Company shall be made solely in the United States.
2. Placements. Each time that the Company wishes to issue and sell Placement Shares
hereunder (each, a “Placement”), it will notify MLV by email notice (or other method
mutually agreed to in writing by the Parties) of the number of Placement Shares, the time period
during which sales are requested to be made, any limitation on the number of Placement Shares that
may be sold in any one day and any minimum price below which sales may not be made (a
“Placement Notice”), the form of which is attached hereto as Schedule 1. The
Placement Notice shall originate from any of the individuals from the Company set forth on
Schedule 3 (with a copy to each of the other individuals from the Company listed on such
schedule), and shall be addressed to each of the individuals from MLV set forth on Schedule
3, as such Schedule 3 may be amended from time to time. It is expressly acknowledged and agreed
that neither the Company nor MLV will have any obligation whatsoever with respect to a Placement or
any Placement Shares unless and until the Company delivers a Placement Notice to MLV and MLV does
not decline such Placement Notice pursuant to the terms set forth below, and then only upon the
terms specified therein and herein. Subject to the foregoing sentence, the Placement Notice shall
be effective unless and until (i) MLV declines to accept the terms contained therein for any
reason, in its sole discretion, (ii) the entire amount of the Placement Shares set forth therein
have been sold, (iii) the Company suspends or terminates the Placement Notice or (iv) the Agreement
has been terminated under the provisions of Section 13. The amount of any discount, commission or
other compensation to be paid by the Company to MLV in connection with the sale of the Placement
Shares shall be calculated in accordance with the terms set forth in
3
Schedule 2. In the event of a conflict between the terms of this Agreement and the
terms of a Placement Notice, the terms of the Placement Notice will control.
3. Sale of Placement Shares by MLV.
(a) Subject to the terms and conditions of this Agreement, MLV, for the period specified in
the Placement Notice, and unless the sale of the Placement Shares described therein has been
suspended or otherwise terminated in accordance with the terms of this Agreement, will use its
commercially reasonable efforts consistent with its normal trading and sales practices and
applicable state and federal laws, rules and regulations and the rules of NASDAQ (“NASDAQ” and,
together with the Toronto Stock Exchange, the “Exchanges”), to sell the Placement Shares up
to the amount specified, and otherwise in accordance with the terms of such Placement Notice. MLV
will provide written confirmation to the Company no later than the opening of the Trading Day (as
defined below) immediately following the Trading Day on which it has made sales of Placement Shares
hereunder setting forth the number of Placement Shares sold on such day, the compensation payable
by the Company to MLV pursuant to Section 2 with respect to such sales, and the Net
Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by
MLV (as set forth in Section 5(b)) from the gross proceeds that it receives from such
sales. Subject to the terms of the Placement Notice, MLV may sell Placement Shares only by methods
deemed to be an “at-the-market distribution” as defined in Section 1.1 of NI 44-102, including
without limitation sales made directly on NASDAQ or on any other existing trading market for the
Common Shares in the United States. “Trading Day” means any day on which Common Shares are
purchased and sold on the NASDAQ.
(b) During the term of this Agreement, neither MLV nor any of its affiliates or subsidiaries
shall engage in (i) any short sale of any security of the Company or (ii) any sale of any security
of the Company that MLV does not own or any sale which is consummated by the delivery of a security
of the Company borrowed by, or for the account of, MLV. Neither MLV nor any of its affiliates or
subsidiaries shall engage in any proprietary trading or trading for MLV’s (or its affiliates’ or
subsidiaries’) own account.
4. Suspension of Sales. The Company or MLV may, upon notice to the other party in
writing (including by email correspondence to each of the individuals of the other party set forth
on Schedule 3, if receipt of such correspondence is actually acknowledged by any of the
individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed
immediately by verifiable facsimile transmission or email correspondence to each of the individuals
of the other Party set forth on Schedule 3), suspend any sale of Placement Shares;
provided, however, that such suspension shall not affect or impair any party’s obligations with
respect to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the
parties agrees that no such notice under this Section 4 shall be effective against any
other party unless it is made to one of the individuals named on Schedule 3 hereto, as such
Schedule may be amended from time to time.
4
5. Sale and Delivery to MLV; Settlement.
(a) Sale of Placement Shares. On the basis of the representations and warranties
herein contained and subject to the terms and conditions herein set forth, upon MLV’s acceptance of
the terms of a Placement Notice, and unless the sale of the Placement Shares described therein has
been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement,
MLV, for the period specified in the Placement Notice, will use its commercially reasonable efforts
consistent with its normal trading and sales practices and applicable law and regulations to sell
such Placement Shares up to the amount specified, and otherwise in accordance with the terms of
such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that
MLV will be successful in selling Placement Shares, (ii) MLV will incur no liability or obligation
to the Company or any other person or entity if it does not sell Placement Shares for any reason
other than a failure by MLV to use its commercially reasonable efforts consistent with its normal
trading and sales practices to sell such Placement Shares as required under this Agreement and
(iii) MLV shall be under no obligation to purchase Placement Shares on a principal basis pursuant
to this Agreement, except as otherwise agreed by MLV and the Company.
(b) Settlement of Placement Shares. Unless otherwise specified in the applicable
Placement Notice, settlement for sales of Placement Shares will occur on the third (3rd)
Trading Day (or such earlier day as is industry practice for regular-way trading) following the
date on which such sales are made (each, a “Settlement Date”). The amount of proceeds to
be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the
“Net Proceeds”) will be equal to the aggregate sales price received by MLV, after deduction
for (i) MLV’s commission, discount or other compensation for such sales payable by the Company
pursuant to Section 2 hereof, and (ii) any reasonably documented transaction fees imposed
by any governmental or self-regulatory organization in respect of such sales.
(c) Delivery of Placement Shares. MLV has established at its clearing broker a
settlement account for and in the name of the Company, which account is and shall be entirely
controlled and directed by the Company (the “Company Account”). On each Trading Day (“T”)
that MLV makes sales of Placement Shares, MLV shall advise the Company of the number of Placement
Shares sold, the prices at which such Placement Shares were sold, and the net proceeds of such
sales that the Company shall receive. On the immediately following Trading Day (“T+1”), MLV shall
advise the Company that the proceeds of sales of Placement Shares on “T” have been received in the
Company Account. Once the clearing broker has confirmed the receipt of the sales proceeds, the
clearing broker shall, upon direction and instruction of the Company on or before each Settlement
Date, instruct the Company’s transfer agent to electronically transfer the Placement Shares being
sold by crediting the Company Account through the Deposit and Withdrawal at Custodian System of the
Depository Trust Company or by such other means of delivery as may be mutually agreed upon by the
parties hereto, which Placement Shares in all cases shall be freely tradable, transferable,
registered shares in good deliverable form. On each Settlement Date, the clearing broker shall
settle the sale of such Placement Shares on a “delivery-versus-payment” (DVP) basis in accordance
with customary practice and rules of the securities industry. MLV shall, or shall instruct its
clearing broker to, deliver the related Net Proceeds in same day funds to an account designated by
the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its
5
transfer agent (if applicable), defaults in its obligation to deliver Placement Shares on a
Settlement Date through no fault of MLV and provided that MLV has not declined the applicable
Placement Notice, the Company agrees that in addition to and in no way limiting the rights and
obligations set forth in Section 11(a) hereto, it will hold MLV harmless against any loss,
claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out
of or in connection with such default by the Company or its transfer agent (if applicable) and pay
to MLV (without duplication) any commission, discount or other compensation to which it would
otherwise have been entitled absent such default.
(d) Limitations on Offering Size. Under no circumstances shall the Company cause or
request the offer or sale of any Placement Shares if, after giving effect to the sale of such
Placement Shares, the aggregate number of Placement Shares sold pursuant to this Agreement would
exceed the lesser of (A) the Maximum Amount and (B) the amount authorized from time to time to be
issued and sold under this Agreement by the Company’s Board of Directors, and notified to MLV in
writing. Under no circumstances shall the Company cause or request the offer or sale of any
Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from
time to time by the Company’s Board of Directors, and notified to MLV in writing.
6. Representations and Warranties of the Company. The Company represents and warrants
to, and agrees with MLV that as of the date of this Agreement and as of each Applicable Time (as
defined below), unless such representation, warranty or agreement specifies a different time or
time:
(a) Registration Statement and Prospectuses. The Company and, assuming no act or
omission on the part of MLV that would make such statement untrue, the transactions contemplated by
this Agreement meet the requirements for and comply with the conditions for the use of Form F-10
under the Securities Act. The Registration Statement has been filed with the Commission and has
been declared effective under the Securities Act. The U.S. Prospectus Supplement will name MLV as
the agent in the section entitled “Plan of Distribution.” The Company has not received, and has no
notice of, any order of the Commission or a Canadian Commission preventing or suspending the use of
the Registration Statement, or threatening or instituting proceedings for that purpose. The
Registration Statement meets the requirements of Form F-10 under the Securities Act and the offer
and sale of Placement Shares as contemplated hereby meet the requirements of NI 44-102 and comply
in all material respects with said National Instrument. Any statutes, regulations, document or
contracts of a character required to be described in the Registration Statement or the Prospectuses
or to be filed as an exhibit to the Registration Statement have been so described or filed. Copies
of the Registration Statement, the Prospectuses, and any such amendments or supplements and all
documents incorporated by reference therein that were filed with the Commission on or prior to the
date of this Agreement have been delivered, or are available through XXXXX, to MLV and its counsel.
The Company has not distributed and, prior to the later to occur of each Settlement Date and
completion of the distribution of the Placement Shares, will not distribute any offering material
in connection with the offering or sale of the Placement Shares other than the Registration
Statement and the Prospectuses and any Issuer Free Writing Prospectus (as defined below) to which
MLV has consented. The Common Shares are currently listed on the NASDAQ under the trading symbol
“AEZS.” Except as disclosed in the Registration Statement, including the Incorporated
6
Documents, or the Prospectuses, the Company has not, in the 12 months preceding the date
hereof, received notice from the Exchanges to the effect that the Company is not in compliance with
the listing or maintenance requirements of such Exchanges. Except as disclosed in the Registration
Statement, including the Incorporated Documents, or the Prospectuses, the Company has no reason to
believe that it will not in the foreseeable future continue to be in compliance with all such
listing and maintenance requirements, other than compliance with minimum bid or market
capitalization requirements, in respect of which the Company makes no representation or warranty.
(b) No Misstatement or Omission. The Registration Statement, when it became
effective, conformed in all material respects with the requirements of the Securities Act. The U.S.
Prospectus conformed, and any amendment or supplement thereto will conform, on the date thereof, in
all material respects with the requirements of the Securities Act. At each Settlement Date, the
Registration Statement and the U.S. Prospectus, as of such date, will conform in all material
respects with the requirements of the Securities Act. The Registration Statement, when it became
effective, did not, and will not, contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not
misleading. The U.S. Prospectus and any amendment and supplement thereto, on the date thereof and
at each Applicable Time (defined below), did not or will not include an untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading. The documents incorporated by
reference in the U.S. Prospectus did not, and any further documents filed and incorporated by
reference therein will not, when filed with the Commission, contain an untrue statement of a
material fact or omit to state a material fact required to be stated in such document or necessary
to make the statements in such document, in light of the circumstances under which they were made,
not misleading. The foregoing shall not apply to statements in, or omissions from, any such
document which are made in reliance upon, and in conformity with, information furnished to the
Company by MLV specifically for use in the preparation thereof. In addition, the Canadian
Prospectus, and any amendment and supplement thereto, on the date thereof and at each Applicable
Time (defined below), did not or will not include an untrue statement of a material fact or omit to
state a material fact necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading. The documents incorporated by reference in the Canadian
Prospectus did not, and any further documents filed and incorporated by reference therein will not,
when filed with the Canadian Commissions, contain an untrue statement of a material fact or omit to
state a material fact required to be stated in such document or necessary to make the statements in
such document, in light of the circumstances under which they were made, not misleading. The
foregoing shall not apply to statements in, or omissions from, any such document which are made in
reliance upon, and in conformity with, information furnished to the Company by MLV specifically for
use in the preparation thereof. The U.S. Prospectus conforms to the Canadian Prospectus except for
such deletions or changes therefrom and additions thereto as are permitted or required by Form F-10
and the Rules and Regulations.
(c) Conformity with Securities Act and Exchange Act. The documents incorporated by
reference in the Registration Statement, the U.S. Prospectus or any amendment or supplement
thereto, when such documents were or are filed with the Commission under the
7
Securities Act or the Exchange Act, conformed or will conform in all material respects with
the requirements of the Securities Act and the Exchange Act, as applicable.
(d) Financial Information. The consolidated financial statements of the Company
included or incorporated by reference in the Registration Statement, the Prospectuses and the
Issuer Free Writing Prospectuses, if any, together with the related notes and schedules, have been
prepared in conformity in all material respects with applicable accounting requirements and the
published rules and regulations of the Commission with respect thereto as in effect as of the time
of filing. Such financial statements have been prepared in accordance with Canadian generally
accepted accounting principles, consistently applied, during the periods involved and for all
periods ending on or before December 31, 2010, and in accordance with International Financial
Reporting Standards as implemented in Canada for all periods ending on or after January 1, 2011
(except (i) as may be otherwise indicated in such financial statements or the notes thereto, or
(ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may
be condensed or summary statements) and fairly present in all material respects the consolidated
financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated
and the consolidated results of operations and cash flows of the Company at the dates and for the
periods specified (subject, in the case of unaudited statements, to normal year-end audit
adjustments which will not be material, either individually or in the aggregate); the other
financial data with respect to the Company and the Subsidiaries contained or incorporated by
reference in the Registration Statement, the Prospectuses and the Issuer Free Writing Prospectuses,
if any, are accurately and fairly presented and prepared on a basis consistent with the financial
statements and books and records of the Company; there are no financial statements (historical or
pro forma) that are required to be included or incorporated by reference in the Registration
Statement, or the Prospectuses that are not included or incorporated by reference as required; the
Company and the Subsidiaries do not have any material liabilities or obligations, direct or
contingent (including any off-balance sheet obligations), not described in the Registration
Statement (including the exhibits thereto), and the Prospectuses which are required to be described
in the Registration Statement or the Prospectuses (including exhibits thereto and Incorporated
Documents); and all disclosures contained or incorporated by reference in the Registration
Statement, the Prospectuses and the Issuer Free Writing Prospectuses, if any, regarding “non-GAAP
financial measures” (as such term is defined by the rules and regulations of the Commission) comply
in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under
the Securities Act, to the extent applicable.
(e) Conformity with XXXXX Filing. The U.S. Prospectus delivered to MLV for use in
connection with the sale of the Placement Shares pursuant to this Agreement will be identical to
the version of the U.S. Prospectus transmitted to the Commission for filing via XXXXX, except to
the extent permitted by Regulation S-T.
(f) Organization. The Company and each of its Subsidiaries are, and will be on each
Representation Date, duly organized, validly existing as a corporation and in good standing under
the laws of their respective jurisdictions of organization. The Company and each of its
Subsidiaries are, and will be on each Representation Date, duly qualified as a foreign corporation
for transaction of business and in good standing under the laws of each other jurisdiction in which
their respective ownership or lease of property or the conduct of their respective businesses
requires such qualification, and have all corporate power and authority
8
necessary to own or hold their respective properties and to conduct their respective
businesses as described in the Registration Statement and the Prospectuses, except, in each case,
where the failure to be so qualified or in good standing or have such power or authority would not
or would not reasonably be expected to, individually or in the aggregate, have a material adverse
effect on the assets, business, operations, earnings, properties, condition (financial or
otherwise), shareholders’ equity or results of operations of the Company and the Subsidiaries (as
defined below) taken as a whole, or prevent or materially interfere with consummation of the
transactions contemplated hereby (a “Material Adverse Effect”).
(g) Subsidiaries. The subsidiaries set forth on Schedule 4 (collectively, the
“Subsidiaries”) are the Company’s only subsidiaries. Except as set forth in the
Registration Statement and in the Prospectuses, the Company owns, directly or indirectly, all of
the equity interests of the Subsidiaries free and clear of any lien, charge, security interest,
encumbrance, right of first refusal or other restriction, and all the equity interests of the
Subsidiaries are validly issued and are fully paid and nonassessable.
(h) No Violation or Default. Neither the Company nor any of its Subsidiaries is: (i)
in violation of its charter or by-laws or similar organizational documents; (ii) in default, and to
the knowledge of the Company no event has occurred that, with notice or lapse of time or both,
would constitute such a default, in the due performance or observance of any term, covenant or
condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or
instrument to which the Company or any of its Subsidiaries is a party or by which the Company or
any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of
its Subsidiaries are subject; or (iii) in violation of any law or statute or any judgment, order,
rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in
the case of each of clauses (ii) and (iii) above, for any such violation or default that would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except
as described in the Registration Statement, Prospectuses or the Incorporated Documents, to the
Company’s knowledge, no other party under any material contract or other agreement to which it or
any of its Subsidiaries is a party is in default in any respect thereunder where such default would
reasonably be expected to have a Material Adverse Effect.
(i) No Material Adverse Change. Since the date of the most recent financial
statements of the Company included or incorporated by reference into the Registration Statement or
Prospectuses prior to each Settlement Date, there has not been (i) any event or condition that has
a Material Adverse Effect, (ii) any material change in the share capital or outstanding long-term
indebtedness of the Company or any of its Subsidiaries, or any dividend or distribution of any kind
declared, paid or made on the capital stock of the Company or any Subsidiary, other than such
change, dividend or distribution which would not have a Material Adverse Effect, and (iii) neither
the Company nor any Subsidiary has sustained any material loss or material interference with its
business from fire, explosion, flood or other calamity, whether or not covered by insurance, or
from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or
governmental or regulatory authority, except in each case as otherwise disclosed in the
Registration Statement or Prospectuses (including any document deemed incorporated by reference
therein). For each Placement, from the Applicable Time until the Settlement Date, neither the
Company nor any Subsidiary will enter into any transaction or
9
agreement, not in the ordinary course of business, that is material to the Company or incur
any liability, obligation, direct or contingent, not in the ordinary course of business, that is
material to the Company, in each case to the extent such transaction, agreement, liability or
obligation would make the statements in the Registration Statement or Prospectuses contain an
untrue statement of material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading.
(j) Capitalization. The issued and outstanding shares of the capital of the Company
have been validly issued, are fully paid and non-assessable. The Company has an authorized, issued
and outstanding capitalization as set forth in the Registration Statement and the Prospectuses as
of the dates referred to therein (other than the grant of additional options under the Company’s
existing stock option plans, or changes in the number of outstanding Common Shares of the Company
due to the issuance of shares upon the exercise or conversion of securities exercisable for, or
convertible into, Common Shares outstanding on the date hereof or as a result of the issuance of
Placement Shares) and such authorized share capital conforms to the description thereof set forth
in the Registration Statement and the Prospectuses. The description of the Common Shares in the
Registration Statement and the Prospectuses is complete and accurate in all material respects.
Except as disclosed in or contemplated by the Registration Statement or the Prospectuses, as of the
date referred to therein, the Company did not have reserved or available for issuance any Common
Shares in respect of options (other than stock options under the Company’s existing stock option
plans), or any rights or warrants to subscribe for, or any securities or obligations convertible
into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of the
capital or other securities of or issued by the Company.
(k) Authorization; Enforceability. The Company has full legal right, power and
authority to enter into this Agreement and perform the transactions contemplated hereby. This
Agreement has been duly authorized and validly executed and delivered by the Company and is a
legal, valid and binding agreement of the Company enforceable in accordance with its terms, except
to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors’ rights generally and by general equitable
principles and (ii) the indemnification and contribution provisions of Section 11 hereof
may be limited by federal or state securities laws and public policy considerations in respect
thereof.
(l) Authorization of Placement Shares. The Placement Shares, when issued and
delivered pursuant to the terms approved by the Board of Directors of the Company, against payment
in full therefor as provided herein, will be duly and validly issued and fully paid and
nonassessable, and will not be subject to preemptive or similar rights. The rights, privileges,
restrictions and conditions attaching to the Placement Shares, when issued, will conform in all
material respects to the description thereof set forth in or incorporated into the Prospectuses.
(m) No Consents Required. No consent, approval, authorization, order, registration or
qualification of or with any court or arbitrator or any governmental or regulatory authority is
required for the execution, delivery and performance by the Company of this Agreement, and the
issuance and sale by the Company of the Placement Shares as contemplated hereby, except for such
consents, approvals, authorizations, orders, exemptions, decisions and
10
registrations or qualifications as may be required under applicable state securities laws or
by the by-laws and rules of the Financial Industry Regulatory Authority (“FINRA”), the
Exchanges, or the AMF in connection with the sale of the Placement Shares by MLV.
(n) No Preferential Rights. Except as set forth in the Registration Statement and the
Prospectuses, (i) no person, as such term is defined in Rule 1-02 of Regulation S-X promulgated
under the Securities Act (each, a “Person”), has the right, contractual or otherwise, to
cause the Company to issue or sell to such Person any Common Shares or shares of any other capital
stock or other securities of the Company (other than upon the exercise of options or warrants to
purchase Common Shares or upon the exercise of options that may be granted from time to time under
the Company’s stock option plans), (ii) no Person has any preemptive rights, rights of first
refusal, or any other rights (whether pursuant to a “poison pill” provision or otherwise) to
purchase any Common Shares or shares of any other capital stock or other securities of the Company
from the Company which have not been duly waived with respect to the offering contemplated hereby,
(iii) except as disclosed in writing to MLV or its representatives in connection with they
transactions contemplated hereby, no Person has the right to act as an underwriter or as a
financial advisor to the Company in connection with the offer and sale of the Common Shares
(excluding, for greater certainty, MLV), and (iv) no Person has the right, contractual or
otherwise, to require the Company to register under the Securities Act any Common Shares or shares
of any other capital stock or other securities of the Company, or to include any such shares or
other securities in the Registration Statement or the offering contemplated thereby, whether as a
result of the filing or effectiveness of the Registration Statement or the sale of the Placement
Shares as contemplated thereby or otherwise, except for such rights as have been waived on or prior
to the date hereof.
(o) Independent Public Accountant. PricewaterhouseCoopers LLP (the
“Accountant”), whose report on the consolidated financial statements of the Company is
filed with the Commission as part of the Company’s most recent Annual Report on Form 20-F filed
with the Commission and incorporated into the Registration Statement, is and, during the periods
covered by its report, was an independent public accountant within the meaning of the Securities
Act and the Public Company Accounting Oversight Board (United States).
(p) No Litigation. Except as set forth in the Registration Statement or the
Prospectuses, there are no legal, governmental or regulatory actions, suits or proceedings pending,
nor, to the Company’s knowledge, any legal, governmental or regulatory investigations, to which the
Company or a Subsidiary is a party or to which any property of the Company or any of its
Subsidiaries is the subject that, individually or in the aggregate, if determined adversely to the
Company or any of its Subsidiaries, would reasonably be expected to have a Material Adverse Effect
or materially and adversely affect the ability of the Company to perform its obligations under this
Agreement; to the Company’s knowledge, no actions, suits or proceedings are threatened or
contemplated by any governmental or regulatory authority or threatened by others that, individually
or in the aggregate, if determined adversely to the Company or any of its Subsidiaries, would
reasonably be expected to have a Material Adverse Effect; and there are no current or pending
legal, governmental or regulatory, actions, suits, proceedings or, to the Company’s knowledge,
investigations that are required under the Securities Act to be described in the U.S. Prospectus
that are not described in the U.S. Prospectus.
11
(q) Licenses and Permits. Except as set forth in the Registration Statement or the
Prospectuses, the Company and each of its Subsidiaries possess or have obtained, all licenses,
certificates, consents, orders, approvals, permits and other authorizations issued by, and have
made all declarations and filings with, the appropriate federal, state, local or foreign
governmental or regulatory authorities that are necessary for the ownership or lease of their
respective properties or the conduct of their respective businesses as described in the
Registration Statement and the Prospectuses (the “Permits”), except where the failure to
possess, obtain or make the same would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. Except as disclosed in the Registration Statement or
the Prospectuses, neither the Company nor any of its Subsidiaries have received written notice of
any proceeding relating to revocation or modification of any such Permit or has any reason to
believe that such Permit will not be renewed in the ordinary course, except where such revocation,
modification or failure to obtain any such renewal would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.
(r) Market Capitalization. To the Company’s knowledge, as of the close of trading on
the Exchange on the Trading Day immediately prior to the date of this Agreement, the aggregate
market value of the outstanding voting equity (as defined in Securities Act Rule 405) of the
Company held by persons other than affiliates of the Company (pursuant to Securities Act Rule 144,
those that directly, or indirectly through one or more intermediaries, control, or are controlled
by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was
greater than $75 million (calculated by multiplying (x) the price at which the common equity of the
Company was last sold on the Exchange on the Trading Day immediately prior to the date of this
Agreement times (y) the number of Non-Affiliate Shares).
(s) No Material Defaults. Neither the Company nor any of the Subsidiaries has
defaulted on any installment on indebtedness for borrowed money or on any rental on one or more
long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to
have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or
15(d) of the Exchange Act since the filing of its last Annual Report on Form 20-F, indicating that
it (i) has failed to pay any dividend or sinking fund installment on preferred stock or (ii) has
defaulted on any installment on indebtedness for borrowed money or on any rental on one or more
long-term leases, which defaults, individually or in the aggregate, could reasonably be expected to
have a Material Adverse Effect.
(t) Certain Market Activities. Neither the Company, nor any of the Subsidiaries, nor
any of their respective directors, officers or controlling persons has taken, directly or
indirectly, any action designed, or that has constituted or might reasonably be expected to cause
or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of the Placement Shares.
(u) Broker/Dealer Relationships. Neither the Company nor any of the Subsidiaries or
any related entities (i) is required to register as a “broker” or “dealer” in accordance with the
provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries,
controls or is a “person associated with a member” or “associated person of a member” (within the
meaning set forth in the FINRA Manual).
12
(v) No Reliance. The Company has not relied upon MLV or legal counsel for MLV for any
legal, tax or accounting advice in connection with the offering and sale of the Placement Shares.
(w) Taxes. The Company and each of its Subsidiaries have filed all U.S. federal,
state, local and foreign tax returns which have been required to be filed and paid all taxes shown
thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to do so would not reasonably be expected to have
a Material Adverse Effect. Except as otherwise disclosed in or contemplated by the Registration
Statement or the Prospectuses, no tax deficiency has been determined adversely to the Company or
any of its Subsidiaries which has had a Material Adverse Effect. The Company has no knowledge of
any federal, state or other governmental tax deficiency, penalty or assessment which has been or
might be asserted or threatened against it which could have a Material Adverse Effect.
(x) Title to Real and Personal Property. Except as set forth in the Registration
Statement or the Prospectuses, the Company and its Subsidiaries have good and valid title in fee
simple to all items of real property and good and valid title to all personal property (excluding
Intellectual Property, which is addressed below) described in the Registration Statement or
Prospectuses as being owned by them that are material to the businesses of the Company or such
Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those that
(i) do not materially interfere with the use made and proposed to be made of such property by the
Company and any of its Subsidiaries or (ii) would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect. Any real property described in the Registration
Statement or Prospectuses as being leased by the Company and any of its Subsidiaries is held by
them under valid, existing and enforceable leases, except those that (A) do not materially
interfere with the use made or proposed to be made of such property by the Company or any of its
Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate, to have a
Material Adverse Effect.
(y) Intellectual Property. Except as set forth in the Registration Statement or the
Prospectuses, to the Company’s knowledge, the Company and its Subsidiaries own or have obtained
adequate enforceable rights to use all patents, patent applications, trademarks (both registered
and unregistered), service marks, trade names, trademark registrations, service xxxx registrations,
copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) (collectively, the
“Intellectual Property”), necessary for the conduct of their respective businesses as
conducted as of the date hereof, except to the extent that the failure to own or to have obtained
adequate rights to use such Intellectual Property would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; except as disclosed in writing to MLV,
neither the Company nor any of its Subsidiaries has received any written notice of any claim of
infringement or conflict which asserted Intellectual Property rights of others, which infringement
or conflict, if the subject of an unfavorable decision, would result in a Material Adverse Effect;
there are no pending, or to the Company’s knowledge, threatened judicial proceedings or
interference proceedings against the Company or its Subsidiaries challenging the Company’s or its
Subsidiaries’ rights in or to or the validity of the scope of any of the Company’s or its
Subsidiaries’ material patents, patent applications or proprietary information, except for such
13
proceedings which would not reasonably be expected to have a Material Adverse Effect; to the
Company’s knowledge, no other entity or individual has any right or claim in any of the Company’s
or its Subsidiaries’ owned material patents, patent applications or any patent to be issued
therefrom by virtue of any contract, license or other agreement entered into between such entity or
individual and the Company or a Subsidiary or by any non-contractual obligation of the Company or a
Subsidiary, other than by written licenses granted by the Company or a Subsidiary, except for such
rights or claims which would not reasonably be expected to have a Material Adverse Effect; the
Company and its Subsidiaries have not received any written notice of any claim challenging the
rights of the Company or a Subsidiary in or to any Intellectual Property owned, licensed or
optioned by the Company or such Subsidiary which claim, if the subject of an unfavorable decision,
would result in a Material Adverse Effect.
(z) Environmental Laws. Except as set forth in the Registration Statement or the
Prospectuses, the Company and its Subsidiaries (i) are in compliance with any and all applicable
federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the
protection of human health and safety, the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (collectively, “Environmental Laws”); (ii) have received and are
in compliance with all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses as described in the Registration
Statement and the Prospectuses; and (iii) have not received written notice of any actual or
potential liability for the investigation or remediation of any disposal or release of hazardous or
toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses (i),
(ii) or (iii) above, for any such failure to comply or failure to receive required permits,
licenses, other approvals or notice or liability as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.
(aa) Disclosure Controls. The Company maintains disclosure controls and procedures
and internal controls over financial reporting (each as defined in Rule 13a-15 under the Exchange
Act) that comply with the requirements of the Exchange Act. The Company is not aware of any
material weaknesses in its internal control over financial reporting (other than as set forth in
the Registration Statement or U.S. Prospectus). Since the date of the latest audited financial
statements of the Company included in the Prospectuses, there has been no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the Company’s internal control over financial reporting (other than as set forth
in the Prospectus). The Company’s certifying officers have evaluated the effectiveness of the
Company’s disclosure controls and procedures as of a date within 90 days prior to the filing date
of the Annual Report on Form 20-F for the fiscal year most recently filed with the Commission (such
date, the “Evaluation Date”). The Company presented in its Annual Report on Form 20-F most
recently filed with the Commission the conclusions of the certifying officers about the
effectiveness of the disclosure controls and procedures based on their evaluations as of the
Evaluation Date.
(bb) Xxxxxxxx-Xxxxx. Except as set forth in the Registration Statement or
Prospectuses, there is and has been no failure on the part of the Company or, to the knowledge of
the Company, any of the Company’s directors or officers, in their capacities as such, to comply
with any applicable provisions of the Xxxxxxxx-Xxxxx Act of 2002 and the rules and regulations
promulgated thereunder. Each of the principal executive officer and the principal financial
14
officer of the Company (or each former principal executive officer of the Company and each
former principal financial officer of the Company as applicable) has made all certifications
required by Sections 302 and 906 of the Xxxxxxxx-Xxxxx Act. For purposes of the preceding
sentence, “principal executive officer” and “principal financial officer” shall have the meanings
given to such terms in the Xxxxxxxx-Xxxxx Act.
(cc) Finder’s Fees. Neither the Company nor any of the Subsidiaries has incurred any
liability for any finder’s fees, brokerage commissions or similar payments in connection with the
transactions herein contemplated, except as may otherwise exist with respect to MLV pursuant to
this Agreement.
(dd) Labor Disputes. Except as disclosed in the Registration Statement or
Prospectuses, no labor disturbance by or dispute with employees of the Company or any of its
Subsidiaries exists or, to the knowledge of the Company, is threatened, in either case which would
reasonably be expected to result in a Material Adverse Effect
(ee) Investment Company Act. The Company, after giving effect to the offering and
sale of the Placement Shares, will not be an “investment company” or an entity “controlled” by an
“investment company,” as such terms are defined in the Investment Company Act of 1940, as amended
(the “Investment Company Act”).
(ff) Operations. The operations of the Company and its Subsidiaries are and have been
conducted at all times in compliance in all material respects with applicable financial record
keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions to which the Company or its
Subsidiaries are subject, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any governmental agency having
jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would
not reasonably be expected to result in a Material Adverse Effect; and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is
pending or, to the knowledge of the Company, threatened.
(gg) Off-Balance Sheet Arrangements. Except as disclosed in the Registration
Statement or Prospectuses, there are no transactions, arrangements and other relationships between
and/or among the Company, and/or, to the knowledge of the Company, any of its Subsidiaries and any
unconsolidated entity, including, but not limited to, any structural finance, special purpose or
limited purpose entity (each, an “Off Balance Sheet Transaction”) that could reasonably be
expected to affect materially the Company’s liquidity or the availability of or requirements for
its capital resources.
(hh) Underwriter Agreements. The Company is not a party to any agreement with an
agent or underwriter for any other “at-the-market” transaction under Part 9 of NI 44-102 or
pursuant to General Instruction II.L of Form F-10.
(ii) ERISA. To the knowledge of the Company, (i) each material employee benefit plan,
within the meaning of Section 3(3) of the Employee Retirement Income Security
15
Act of 1974, as amended (“ERISA”), that is maintained, administered or contributed to
by the Company or any of its Subsidiaries (other than a Multiemployer Plan, within the meaning of
Section 3(37) of ERISA) for employees or former employees of the Company and any of its
Subsidiaries has been maintained in material compliance with its terms and the requirements of any
applicable statutes, orders, rules and regulations, including but not limited to ERISA and the
Internal Revenue Code of 1986, as amended (the “Code”); (ii) no prohibited transaction,
within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would
result in material liability to the Company with respect to any such plan (excluding transactions
effected pursuant to a statutory or administrative exemption); and (iii) for each such plan that is
subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no “accumulated
funding deficiency” as defined in Section 412 of the Code has been incurred, whether or not waived,
and the fair market value of the assets of each such plan (excluding for these purposes accrued but
unpaid contributions) equals or exceeds the present value of all benefits accrued under such plan
determined using reasonable actuarial assumptions, other than, in the case of (i), (ii) and (iii)
above, as would not reasonably be expected to have a Material Adverse Effect.
(jj) Insurance. The Company and each of its Subsidiaries carry, or are covered by,
insurance in such amounts and covering such risks as the Company and each of its Subsidiaries
reasonably believe are adequate for the conduct of their businesses and as is customary for
companies of similar size engaged in similar businesses in similar industries.
(kk) No Improper Practices. (i) Neither the Company nor, to the Company’s knowledge,
the Subsidiaries, nor to the Company’s knowledge, any of their respective executive officers has,
in the past five years, made any unlawful contributions to any candidate for any political office
(or failed fully to disclose any contribution in violation of law) or made any contribution or
other payment to any official of, or candidate for, any federal, state, municipal, or foreign
office or other person charged with similar public or quasi-public duty in violation of any law;
(ii) no relationship, direct or indirect, exists between or among the Company or, to the Company’s
knowledge, any Subsidiary, or any affiliate of them, on the one hand, and the directors, officers
and stockholders of the Company or, to the Company’s knowledge, any Subsidiary, on the other hand,
that is required by the Securities Act to be described in the Registration Statement and the
Prospectuses that is not so described; (iii) the Company has not offered, or caused any placement
agent to offer, Common Shares to any person with the intent to influence unlawfully (A) a customer
or supplier of the Company or any Subsidiary to alter the customer’s or supplier’s level or type of
business with the Company or any Subsidiary or (B) a trade journalist or publication to write or
publish favorable information about the Company or any Subsidiary or any of their respective
products or services, and, (iv) neither the Company nor any Subsidiary nor, to the Company’s
knowledge, any employee or agent of the Company or any Subsidiary has made any payment of funds of
the Company or any Subsidiary or received or retained any funds in violation of the Foreign Corrupt
Practices Act of 1977.
(ll) Status Under the Securities Act. The Company was not and will not be at any
Settlement Date an ineligible issuer as defined in Rule 405 under the Securities Act.
(mm) No Conflicting Statements in an Issuer Free Writing Prospectus. Each Issuer Free
Writing Prospectus, as of its issue date and as of each Applicable Time (as defined in
16
Section 24 below), did not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement or the
Prospectuses, including any incorporated document deemed to be a part thereof that has not been
superseded or modified. The foregoing sentence does not apply to conflicting information in any
Issuer Free Writing Prospectus based upon and in conformity with written information furnished to
the Company by MLV specifically for use therein.
(nn) No Conflicts. Neither the execution of this Agreement, nor the issuance,
offering or sale of the Placement Shares, nor the consummation of any of the transactions
contemplated herein, nor the compliance by the Company with the terms and provisions hereof will
conflict with, or will result in a breach of, any of the terms and provisions of, or has
constituted or will constitute a default under, or has resulted in or will result in the creation
or imposition of any lien, charge or encumbrance upon any property or assets of the Company
pursuant to the terms of any contract or other agreement to which the Company may be bound or to
which any of the property or assets of the Company is subject, except (i) such conflicts, breaches
or defaults as may have been waived and (ii) such conflicts, breaches and defaults that would not
reasonably be expected to have a Material Adverse Effect; nor will such action result (x) in any
violation of the provisions of the organizational or governing documents of the Company, or (y) in
any material violation of the provisions of any statute or any order, rule or regulation applicable
to the Company or of any court or of any federal, state or other regulatory authority or other
government body having jurisdiction over the Company, except where such violation would not
reasonably be expected to have a Material Adverse Effect.
(oo) Clinical Studies. The clinical, pre-clinical and other studies and tests
conducted by or, to the knowledge of the Company, on behalf of the Company were, and, if still
pending, are being, conducted in accordance in all material respects with all statutes, laws, rules
and regulations, as applicable (including, without limitation, the U.S. Federal and Drug
Administration’s (the “FDA”) Good Laboratory Practices and Good Clinical Practices as well as all
other applicable rules, regulations, or requirements of the FDA or any foreign, federal, state or
local governmental or regulatory authority performing functions similar to those performed by the
FDA). Except as set forth in the Registration Statement and Prospectuses, the Company has not
received any written notices or other written correspondence from the FDA or any other foreign,
federal, state or local governmental or regulatory authority performing functions similar to those
performed by the FDA requiring the Company to terminate or suspend any ongoing clinical or
pre-clinical studies or tests.
(pp) Compliance Program. Except as disclosed in the Registration Statement and the
Prospectuses, the Company has established and administers a compliance program applicable to the
Company, to assist the Company and the directors, officers and employees of the Company in
complying with applicable regulatory guidelines (including, without limitation, those administered
by the FDA and any other foreign, federal, state or local governmental or regulatory authority
performing functions similar to those performed by the FDA) except where such noncompliance would
not reasonably be expected to have a Material Adverse Effect.
(qq) OFAC. (i) To the knowledge of the Company, neither the Company nor any of its
Subsidiaries (collectively, the “Entity”), nor any director, officer, employee, agent or
17
representative of the Entity, is an individual or entity (in this paragraph (qq),
“Person”) that is, or is owned or controlled by a Person that is:
(A) the subject of any sanctions administered or enforced by the U.S.
Department of Treasury’s Office of Foreign Assets Control (“OFAC”), the
European Union (“EU”) or other relevant sanctions authority (collectively,
“Sanctions”), or
(B) located, organized or resident in a country or territory that is the
subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran,
North Korea, Sudan and Syria).
(ii) The proceeds of the issuance and sale of the Placement Shares will be applied by the
Entity in good faith as described under the caption “Use of Proceeds” in each U.S. Prospectus
Supplement and the Prospectuses, and not with the result that any Person, directly or indirectly,
shall have used the proceeds of the offering, or lent, contributed or otherwise made available
such proceeds to any subsidiary, joint venture partner or other Person:
(A) to fund or facilitate any activities or business of or with any Person or
in any country or territory that, at the time of such funding or facilitation, is
the subject of Sanctions; or
(B) in any other manner that will result in a violation of Sanctions by any
Person (including any Person participating in the offering, whether as underwriter,
advisor, investor or otherwise).
(iii) Except as described in the Registration Statement and the Prospectuses, during the
past 5 years, the Entity has not knowingly engaged in or is not now knowingly engaged in, any
dealings or transactions with any Person, or in any country or territory, that at the time of the
dealing or transaction is or was the subject of Sanctions.
(rr) Stock Transfer Taxes. On each Settlement Date, all stock transfer or other taxes
(other than income taxes) which are required to be paid in connection with the sale and transfer of
the Placement Shares to be sold hereunder will be, or will have been, fully paid or provided for by
the Company and all laws imposing such taxes will be or will have been fully complied with in all
material respects.
(ss) Foreign Private Issuer. The Company is a “foreign private issuer” as such term is
defined in Rule 3b-4 under the Exchange Act and in Rule 405 under the Securities Act.
(tt) AMF. The Company has received a valid exemption order/decision from the AMF
pursuant to, inter alia, Section 263 of the Securities Act (Québec) with respect to this Agreement
and the offering of Placement Shares hereunder, and the AMF has not withdrawn or modified such
exemption order/decision.
(uu) Filed All Documents. The Company has filed all documents or information required
to be filed by it under Canadian Securities Laws, the Securities Act, the Exchange Act, the Rules
and Regulations and the rules, regulations and policies of the
18
Exchanges; all press releases, material change reports, annual information forms, financial
statements, management proxy circulars and other documents filed by or on behalf of the Company
with the Exchanges, the Canadian Commissions in each of the provinces where the Company is a
reporting issuer (or the equivalent), as of their respective dates, did not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading and did not contain a misrepresentation (as defined under Canadian Securities Laws)
at the time at which it was filed; except as otherwise disclosed on Schedule 5, the Company has not
filed any confidential material change report or any document requesting confidential treatment
with any securities regulatory authority or regulator or any exchange that at the date hereof
remains confidential.
Any certificate signed by an authorized officer of the Company and delivered to MLV or to
counsel for MLV pursuant to or in connection with this Agreement shall be deemed to be a
representation and warranty by the Company, as applicable, to MLV as to the matters set forth
therein.
7. Covenants of the Company. The Company covenants and agrees with MLV that:
(a) Registration Statement Amendments. After the date of this Agreement and during
any period in which a U.S. Prospectus relating to any Placement Shares is required to be delivered
by MLV under the Securities Act (the “Prospectus Delivery Period”), (i) the Company will
notify MLV promptly of the time when any subsequent amendment to the Registration Statement, other
than documents incorporated by reference or amendments not related to any Placement, has been filed
with the Commission and/or has become effective or any subsequent supplement to the Prospectus has
been filed and of any request by the Commission for any amendment or supplement to the Registration
Statement or Prospectus or for additional information related to the Placement, (ii) the Company
will not file any amendment or supplement to the Registration Statement or Prospectus relating to
the Placement Shares unless a copy thereof has been submitted to MLV within a reasonable period of
time before the filing and MLV has not reasonably objected thereto (provided, however, (A) that the
failure of MLV to make such objection shall not relieve the Company of any obligation or liability
hereunder, or affect MLV’s right to rely on the representations and warranties made by the Company
in this Agreement, (B) that the Company has no obligation to provide MLV any advance copy of such
filing or to provide MLV an opportunity to object to such filing if such filing does not name MLV
or does not relate to the transactions contemplated hereunder, and (C) that the only remedy MLV
shall have with respect to the failure by the Company to provide MLV with such copy shall be to
cease making sales under this Agreement) and the Company will furnish to MLV at the time of filing
thereof a copy of any document that upon filing is deemed to be incorporated by reference into the
Registration Statement or Prospectus, except for those documents available via XXXXX; and (iii) the
Company will cause each amendment or supplement to the Prospectus to be filed with the Commission
as required pursuant to General Instruction II.E of Form F-10 or, in the case of any document to be
incorporated therein by reference, to be filed with the Commission as required pursuant to the
Exchange Act, within the time period prescribed (the determination to file or not to file any
amendment or supplement with the Commission under this
19
Section 7(a), based on the Company’s reasonable opinion or reasonable objections,
shall be made exclusively by the Company).
(b) Notice of Commission Stop Orders. During the Prospectus Delivery Period, the
Company will advise MLV, promptly after it receives notice or obtains knowledge thereof, of the
issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of
the Registration Statement, of the suspension of the qualification of the Placement Shares for
offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding for any
such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance
of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company
will advise MLV promptly after it receives any request by the Commission for any amendments to the
Registration Statement or any amendment or supplements to the U.S. Prospectus or any Issuer Free
Writing Prospectus or for additional information related to the offering of the Placement Shares or
for additional information related to the Registration Statement, the U.S. Prospectus or any Issuer
Free Writing Prospectus.
(c) Delivery of Prospectus; Subsequent Changes. During the Prospectus Delivery
Period, the Company will use its best efforts to comply with all requirements imposed upon it by
the Securities Act and Canadian Securities Laws, as from time to time in force, and to file on or
before their respective due dates all reports and any definitive proxy or information statements
required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14,
15(d) or any other provision of or under the Exchange Act. If during the Prospectus Delivery Period
any event occurs as a result of which the U.S. Prospectus as then amended or supplemented would
include an untrue statement of a material fact or omit to state a material fact necessary to make
the statements therein, in the light of the circumstances then existing, not misleading, or if
during the Prospectus Delivery Period it is necessary to amend or supplement the Registration
Statement or U.S. Prospectus to comply with the Securities Act, the Company will promptly notify
MLV to suspend the offering of Placement Shares during such period and the Company will promptly
amend or supplement the Registration Statement or U.S. Prospectus (at the expense of the Company)
so as to correct such statement or omission or effect such compliance.
(d) Listing of Placement Shares. During the Prospectus Delivery Period, the Company
will use its reasonable best efforts to cause the Placement Shares to be listed on the Exchanges
and to qualify the Placement Shares for sale under the state securities laws in the United States
and to continue such qualification in effect so long as required for the distribution of the
Placement Shares; provided, however, that the Company shall not be required in connection therewith
to qualify as a foreign corporation or dealer in securities or file a general consent to service of
process in any jurisdiction.
(e) Delivery of Registration Statement and Prospectus. The Company will furnish to
MLV and its counsel (at the expense of the Company) copies of the Registration Statement, the
Prospectus (including all documents incorporated by reference therein) and all amendments and
supplements to the Registration Statement or U.S. Prospectus that are filed with the Commission
during the Prospectus Delivery Period (including all documents filed with the Commission during
such period that are deemed to be incorporated by reference therein), in each case as soon as
reasonably practicable and in such quantities as MLV may from time to time
20
reasonably request and, at MLV’s request, will also furnish copies of the Prospectus to each
exchange or market on which sales of the Placement Shares may be made; provided, however, that the
Company shall not be required to furnish any document (other than the U.S. Prospectus) to MLV to
the extent such document is available on XXXXX.
(f) Earnings Statement. The Company will make generally available to its security
holders as soon as practicable, but in any event not later than 15 months after the end of the
Company’s current fiscal quarter, an earnings statement covering a 12-month period that satisfies
the provisions of Section 11(a) and Rule 158 of the Securities Act.
(g) Use of Proceeds. The Company will use the Net Proceeds as described in the
Prospectus in the section entitled “Use of Proceeds.”
(h) Notice of Other Sales. During the Prospectus Delivery Period, the Company shall
provide MLV with written notice as promptly as reasonably possible before it will, directly or
indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of
any Common Shares (other than the Placement Shares offered pursuant to this Agreement) or
securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase
or acquire, Common Shares; provided, however, that such notice will not be required in connection
with the Company’s issuance or sale of (i) Common Shares, options to purchase Common Shares or
Common Shares issuable upon the exercise of options, pursuant to any employee or director stock
option or benefits plan, stock ownership plan or dividend reinvestment plan (but not Common Shares
subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether
now in effect or hereafter implemented; (ii) Common Shares issuable upon conversion of securities
or the exercise of warrants, options or other rights in effect or disclosed as outstanding in the
Registration Statement and the Prospectus, and (iii) Common Shares, or securities convertible into
or exercisable for Common Shares, issued pursuant to consulting arrangements or service provider
arrangements the primary purpose of which is not to raise capital, unless, in each case, such
arrangements are required to be disclosed on a current report on Form 6-K. In addition, while this
Agreement is in force and shall not have expired, terminated or been terminated, during the period
beginning on the fifth (5th) Trading Day immediately prior to the date on which any
Placement Notice is delivered to MLV hereunder and ending on the fifth (5th) Trading Day
immediately following the final Settlement Date with respect to Placement Shares sold pursuant to
such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the
sale of all Placement Shares covered by a Placement Notice, the date of such suspension or
termination), the Company will not, directly or indirectly, sell, contract to sell, grant any
option to sell or otherwise dispose of any Common Shares (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares,
warrants or any rights to purchase or acquire, Common Shares in any other “at-the-market” offering.
(i) Change of Circumstances. The Company will, at any time during the pendency of a
Placement Notice given hereunder, advise MLV promptly after it shall have received notice or
obtained knowledge thereof, of any information or fact that would alter or affect in any material
respect any opinion, certificate, letter or other document required to be provided to MLV pursuant
to this Agreement.
21
(j) Due Diligence Cooperation. The Company will cooperate with any reasonable due
diligence review conducted by MLV or its representatives in connection with the transactions
contemplated hereby, including, without limitation, providing information and making available
documents and senior corporate officers, during regular business hours and at the Company’s
principal offices or such other location mutually agreed to by the parties, as MLV may reasonably
request.
(k) Required Filings Relating to Placement of Placement Shares. The Company agrees
that on such dates as the Securities Act shall require, the Company will (i) file a prospectus
supplement with the Commission pursuant to General Instruction II.L of Form F-10, which prospectus
supplement will set forth, within the relevant period, the amount of Placement Shares sold through
MLV, the Net Proceeds to the Company and the compensation payable by the Company to MLV with
respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus
supplement to each exchange or market on which such sales were effected as may be required by the
rules or regulations of such exchange or market.
(l) Representation Dates; Certificate. On the date of this Agreement and each time
the Company:
(i) files the U.S. Prospectus relating to the Placement Shares, amends the Registration
Statement by means of a post-effective amendment or amends or supplements the Prospectus
relating to the Placement Shares (other than a prospectus supplement relating solely to an
offering of securities other than the Placement Shares) by means of a sticker or supplement,
but not by means of incorporation of documents by reference into the Registration Statement
or the Prospectus relating to the Placement Shares;
(ii) files an annual report on Form 20-F under the Exchange Act (including any Form 20-F/A
that contains restated financial statements); or
(iii) furnishes its unaudited interim financial statements and management’s discussion and
analysis on Form 6-K under the Exchange Act (each date of filing of one or more of the
documents referred to in clauses (i) through (iii) shall be a “Representation
Date”);
the Company shall furnish MLV with a certificate, in the form attached hereto as Exhibit 7(l). The
requirement to provide a certificate under this Section 7(l) shall be waived for any Representation
Date occurring during a fiscal quarter during which the Company does not intend to sell Placement
Shares prior to the next occurring Representation Date; provided, however, that such waiver shall
not apply for any Representation Date on which the Company files its annual report on Form 20-F.
Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares
following a Representation Date when the Company relied on such waiver and did not provide MLV with
a certificate under this Section 7(l), then before the Company delivers the Placement Notice or MLV
sells any Placement Shares, the Company shall provide MLV with a certificate, in the form attached
hereto as Exhibit 7(l), dated the date of the Placement Notice.
(m) Legal Opinions. (1) On the date of this Agreement, and (2) within ten (10)
Trading Days after each Representation Date with respect to which the Company is
22
obligated to deliver a certificate in the form attached hereto as Exhibit 7(l) for which no
waiver is applicable, the Company shall cause to be furnished to MLV written opinions of each of
Xxxxxx Xxxx OR LLP and Ropes & Xxxx LLP (collectively, “Company Counsel”), or other counsel
reasonably satisfactory to MLV, modified, as necessary, to relate to the Registration Statement and
the Prospectus as then amended or supplemented; provided, however, the Company shall be required to
furnish to MLV no more than one opinion per calendar quarter from each Company Counsel; provided,
further, that in lieu of such opinions for subsequent periodic filings under the Exchange Act,
Company Counsel may furnish MLV with a letter (a “Reliance Letter”) to the effect that MLV
may rely on a prior opinion delivered under this Section 7(m) to the same extent as if it were
dated the date of such letter (except that statements in such prior opinion shall be deemed to
relate to the Registration Statement and the Prospectus as amended or supplemented as of the date
of the Reliance Letter).
(n) Comfort Letter. (1) On the date of this Agreement and (2) within ten (10) Trading
Days after the filing by the Company of an annual report on Form 20-F under the Exchange Act, the
Company shall cause its independent accountants to furnish MLV letters (the “Comfort
Letters”), dated the date the Comfort Letter is delivered, which shall meet the requirements
set forth in this Section 7(n). The Comfort Letter from the Company’s independent
accountants shall be in a form and substance reasonably satisfactory to MLV, (i) confirming that
they are an independent public accounting firm within the meaning of the Securities Act and the
PCAOB, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the
financial information and other matters ordinarily covered by accountants’ “comfort letters” to
underwriters in connection with registered public offerings (the first such letter, the
“Initial Comfort Letter”) and (iii) updating the Initial Comfort Letter with any
information that would have been included in the Initial Comfort Letter had it been given on such
date and modified as necessary to relate to the Registration Statement and the U.S. Prospectus, as
amended and supplemented to the date of such letter.
(o) Market Activities. The Company will not, directly or indirectly, (i) take any
action designed to cause or result in, or that constitutes or might reasonably be expected to
constitute, the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Placement Shares or (ii) sell, bid for, or purchase Common
Shares in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the
Placement Shares other than MLV.
(p) Investment Company Act. The Company will conduct its affairs in such a manner so
as to reasonably ensure that neither it nor any of its Subsidiaries will be or become, at any time
prior to the termination of this Agreement, an “investment company,” as such term is defined in the
Investment Company Act.
(q) No Offer to Sell. Other than an Issuer Free Writing Prospectus approved in
advance by the Company and MLV in its capacity as agent hereunder, neither MLV nor the Company
(including its agents and representatives, other than MLV in their capacity as such) will make,
use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405
under the Securities Act), required to be filed with the Commission, that constitutes an offer to
sell or solicitation of an offer to buy Placement Shares hereunder.
23
(r) Xxxxxxxx-Xxxxx Act. The Company and the Subsidiaries will maintain disclosure
controls and procedures and internal controls over financial reporting (each as defined in Rule
13a-15 under the Exchange Act) that comply with the requirements of the Exchange Act.
8. Representations and Covenants of MLV. MLV represents, warrants and covenants to
the Company that
(a) it is duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable
statutes and regulations of each state in which the Placement Shares will be offered and sold,
except such states in which MLV is exempt from registration or such registration is not otherwise
required. MLV shall continue, for the term of this Agreement, to be duly registered as a
broker-dealer under FINRA, the Exchange Act and the applicable statutes and regulations of each
state in which the Placement Shares will be offered and sold, except such states in which MLV is
exempt from registration or such registration is not otherwise required, during the term of this
Agreement. MLV will comply with all applicable law and regulations in connection with the Placement
Shares, including but not limited to Regulation M under the Exchange Act;
(b) neither it, nor any of its affiliates or subsidiaries, shall engage in (i) any short sale
of any security of the Company or (ii) any sale of any security of the Company that MLV does not
own or any sale which is consummated by the delivery of a security of the Company borrowed by, or
for the account of, MLV; and
(c) neither it, nor any of its affiliates or subsidiaries, engages in any proprietary trading
or trading for MLV’s (or its affiliates’ or subsidiaries’) own account.
9. Payment of Expenses.
The Company will pay all expenses incident to the performance of its obligations under this
Agreement, including expenses related to (i) the preparation, filing, including any fees required
by the Commission, and printing of the Registration Statement (including financial statements and
exhibits) as originally filed and of each amendment and supplement thereto and each Issuer Free
Writing Prospectus, in such number as MLV shall reasonably deem necessary, (ii) the preparation,
issuance and delivery of the certificates, if any, for the Placement Shares to MLV, including any
stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes (other
than income taxes) payable upon the sale, issuance or delivery of the Placement Shares to MLV,
(iii) the fees and disbursements of the Company’s counsel, accountants and other advisors, (iv)
the fees and expenses of the transfer agent and registrar for the Common Shares, (v) the filing
fees incident to any review by FINRA of the terms of the sale of the Placement Shares, and (vi) the
fees and expenses incurred in connection with the listing of the Placement Shares on the Exchanges.
MLV shall be responsible for paying all of its own legal counsel’s and other professional advisors’
fees, expenses and disbursements.
10. Conditions to MLV’s Obligations. The obligations of MLV hereunder with respect to
a Placement will be subject to the continuing accuracy and completeness of the representations and
warranties made by the Company herein, to the due performance by the Company of its obligations
hereunder, to the completion by MLV of a due diligence review
24
satisfactory to it in its reasonable judgment, and to the continuing satisfaction (or waiver
by MLV in its sole discretion) of the following additional conditions:
(a) Registration Statement Effective. The Registration Statement shall have become
effective and shall be available for the sale of all Placement Shares contemplated to be issued by
any Placement Notice.
(b) No Material Notices. None of the following events shall have occurred and be
continuing: (i) receipt by the Company of any request for additional information from the
Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement the response to which would require any post-effective amendments or
supplements to the Registration Statement or the Prospectuses; (ii) the issuance by the Commission
or any other federal or state governmental authority of any stop order suspending the effectiveness
of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt
by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; or (iv) the occurrence of any event that requires
the making of any changes in the Registration Statement, the Prospectuses or material documents
incorporated therein so that, in the case of the Registration Statement, it will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading and, that in the case of the
Prospectus, it will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading.
(c) No Misstatement or Material Omission. MLV shall not have advised the Company that
the Registration Statement or U.S. Prospectus, or any amendment or supplement thereto, contains an
untrue statement of fact that in MLV’s reasonable opinion is material, or omits to state a fact
that in MLV’s opinion is material and is required to be stated therein or is necessary to make the
statements therein not misleading.
(d) Material Changes. Except as contemplated in the U.S. Prospectus, or disclosed in
the Company’s reports filed with the Commission, there shall not have been any material adverse
change, on a consolidated basis, in the authorized capital stock of the Company or any Material
Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse
Effect.
(e) Legal Opinions. MLV shall have received the opinions and letters of Company
Counsel required to be delivered pursuant Section 7(m) on or before the date on which such
delivery of such opinions and letters are required pursuant to Section 7(m).
(f) Comfort Letter. MLV shall have received the Comfort Letter required to be
delivered pursuant Section 7(n) on or before the date on which such delivery of such letter
is required pursuant to Section 7(n).
25
(g) Representation Certificate. MLV shall have received the certificate required to
be delivered pursuant to Section 7(l) on or before the date on which delivery of such
certificate is required pursuant to Section 7(l).
(h) No Suspension. Trading in the Common Shares shall not have been suspended on the
Exchanges and the Common Shares shall not have been delisted from the Exchanges.
(i) Other Materials. On each date on which the Company is required to deliver a
certificate pursuant to Section 7(l), the Company shall use its reasonable efforts to
furnish to MLV such appropriate further information, certificates and documents as MLV may
reasonably request and which are usually and customarily furnished by an issuer of securities in
connection with a securities offering. All such opinions, certificates, letters and other
documents will be in compliance with the provisions hereof. The Company will furnish MLV with such
conformed copies of such opinions, certificates, letters and other documents as MLV shall
reasonably request.
(j) Securities Act Filings Made. All filings with the Commission required by Form
F-10 under the Securities Act to have been filed prior to the issuance of any Placement Notice
hereunder shall have been made within the applicable time period prescribed for such filing by Form
F-10.
(k) Approval for Listing. The Placement Shares shall either have been approved for
listing on the NASDAQ, subject only to notice of issuance, or the Company shall have filed an
application for listing of the Placement Shares on the Exchange at, or prior to, the issuance of
any Placement Notice.
(l) No Termination Event. There shall not have occurred any event that would permit
MLV to terminate this Agreement pursuant to Section 13(a).
11. Indemnification and Contribution.
(a) Company Indemnification. The Company agrees to indemnify and hold harmless MLV,
its partners, members, directors, officers, employees and agents and each person, if any, who
controls MLV within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act against any and all loss, liability, claim, damage and expense whatsoever (including any and
all investigative, legal and other expenses reasonably incurred in connection with, and any amount
paid in settlement of, any action, suit or proceedings or any claim asserted), as incurred, joint
or several, arising out of or based upon any untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement (or any amendment thereto), or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make
the statements therein not misleading, or arising out of any untrue statement or alleged untrue
statement of a material fact included in any related Issuer Free Writing Prospectus or the
Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom
of a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that
this indemnity agreement shall not apply to any loss, liability, claim, damage or
26
expense to the extent arising out of any untrue statement or omission or alleged untrue
statement or omission made in reliance upon and in conformity with written information furnished to
the Company by MLV expressly for use in the Registration Statement (or any amendment thereto), or
in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement
thereto).
(b) MLV Indemnification. MLV agrees to indemnify and hold harmless the Company and
its directors and each officer of the Company who signed the Registration Statement, and each
person, if any, who (i) controls the Company within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the
Company against any and all loss, liability, claim, damage and expense described in the indemnity
contained in Section 11(c), as incurred, but only insofar as such loss, liability, claim,
damage and expense arise out of or are based, directly or indirectly, upon untrue statements or
omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any
amendments thereto), the Prospectus (or any amendment or supplement thereto) or any Free Writing
Prospectus in reliance upon and in conformity with information furnished to the Company in writing
by MLV expressly for use therein.
(c) Procedure. Any party that proposes to assert the right to be indemnified under
this Section 11 will, promptly after receipt of notice of commencement of any action
against such party in respect of which a claim is to be made against an indemnifying party or
parties under this Section 11, notify each such indemnifying party of the commencement of
such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying
party will not relieve the indemnifying party from (i) any liability that it might have to any
indemnified party otherwise than under this Section 11 and (ii) any liability that it may
have to any indemnified party under the foregoing provision of this Section 11 unless, and
only to the extent that, such omission results in the forfeiture or material impairment of
substantive rights or defenses by the indemnifying party. If any such action is brought against
any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying
party will be entitled to participate in and, to the extent that it elects by delivering written
notice to the indemnified party promptly after receiving notice of the commencement of the action
from the indemnified party, jointly with any other indemnifying party similarly notified, to assume
the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after
notice from the indemnifying party to the indemnified party of its election to assume the defense,
the indemnifying party will not be liable to the indemnified party for any legal or other expenses
except as provided below. The indemnified party will have the right to employ its own counsel in
any such action, but the fees, expenses and other charges of such counsel will be at the expense of
such indemnified party unless (1) the employment of counsel by the indemnified party has been
authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded
(based on advice of counsel) that there may be legal defenses available to it or other indemnified
parties that are different from or in addition to those available to the indemnifying party, (3) a
conflict or potential conflict exists (based on advice of counsel to the indemnified party) between
the indemnified party and the indemnifying party (in which case the indemnifying party will not
have the right to direct the defense of such action on behalf of the indemnified party) or (4) the
indemnifying party has not in fact employed counsel to assume the defense of such action within a
reasonable time after receiving notice of the commencement of the action, in each of which cases
the reasonable fees, disbursements and other charges of
27
counsel will be at the expense of the indemnifying party or parties. It is understood that
the indemnifying party or parties shall not, in connection with any proceeding or related
proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other
charges of more than one separate firm admitted to practice in such jurisdiction at any one time
for all such indemnified party or parties. All such fees, disbursements and other charges will be
reimbursed by the indemnifying party promptly after the indemnifying party receives a written
invoice relating to fees, disbursements and other charges in reasonable detail. An indemnifying
party will not, in any event, be liable for any settlement of any action or claim effected without
its written consent. No indemnifying party shall, without the prior written consent of each
indemnified party, settle or compromise or consent to the entry of any judgment in any pending or
threatened claim, action or proceeding relating to the matters contemplated by this Section
11 (whether or not any indemnified party is a party thereto), unless such settlement,
compromise or consent (1) includes an unconditional release of each indemnified party from all
liability arising out of such litigation, investigation, proceeding or claim and (2) does not
include a statement as to or an admission of fault, culpability or a failure to act by or on behalf
of any indemnified party.
(d) Contribution. In order to provide for just and equitable contribution in
circumstances in which the indemnification provided for in the foregoing paragraphs of this
Section 11 is applicable in accordance with its terms but for any reason is held to be
unavailable from the Company or MLV, the Company and MLV will contribute to the total losses,
claims, liabilities, expenses and damages (including any investigative, legal and other expenses
reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or
proceeding or any claim asserted, but after deducting any contribution received by the Company from
persons other than MLV, such as persons who control the Company within the meaning of the
Securities Act, officers of the Company who signed the Registration Statement and directors of the
Company, who also may be liable for contribution) to which the Company and MLV may be subject in
such proportion as shall be appropriate to reflect the relative benefits received by the Company on
the one hand and MLV on the other hand. The relative benefits received by the Company on the one
hand and MLV on the other hand shall be deemed to be in the same proportion as the total net
proceeds from the sale of the Placement Shares (net of commissions to MLV but before deducting
expenses) received by the Company bear to the total compensation received by MLV (before deducting
expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the
allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of
contribution shall be made in such proportion as is appropriate to reflect not only the relative
benefits referred to in the foregoing sentence but also the relative fault of the Company, on the
one hand, and MLV, on the other hand, with respect to the statements or omission that resulted in
such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other
relevant equitable considerations with respect to such offering. Such relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or MLV, the intent of the parties and their relative knowledge, access to
information and opportunity to correct or prevent such statement or omission. The Company and MLV
agree that it would not be just and equitable if contributions pursuant to this Section
11(d) were to be determined by pro rata allocation or by any other method of allocation that
does not take into account the equitable considerations referred to herein. The amount paid or
payable by an indemnified party as a
28
result of the loss, claim, liability, expense, or damage, or action in respect thereof,
referred to above in this Section 11(d) shall be deemed to include, for the purpose of this
Section 11(d), any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending any such action or claim to the extent consistent with
Section 11(c) hereof. Notwithstanding the foregoing provisions of this Section 11(d), MLV
shall not be required to contribute any amount in excess of the commissions received by it under
this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. For purposes of this Section 11(d), any
person who controls a party to this Agreement within the meaning of the Securities Act, and any
officers, directors, partners, employees or agents of MLV, will have the same rights to
contribution as that party, and each officer and director of the Company who signed the
Registration Statement will have the same rights to contribution as the Company, subject in each
case to the provisions hereof. Any party entitled to contribution, promptly after receipt of
notice of commencement of any action against such party in respect of which a claim for
contribution may be made under this Section 11(d), will notify any such party or parties
from whom contribution may be sought, but the omission to so notify will not relieve that party or
parties from whom contribution may be sought from any other obligation it or they may have under
this Section 11(d) except to the extent that the failure to so notify such other party
materially prejudiced the substantive rights or defenses of the party from whom contribution is
sought. Except for a settlement entered into pursuant to the last sentence of Section
11(c) hereof, no party will be liable for contribution with respect to any action or claim
settled without its written consent if such consent is required pursuant to Section 11(c)
hereof.
12. Representations and Agreements to Survive Delivery. The indemnity and contribution
agreements contained in Section 11 of this Agreement and all representations and warranties
of the Company herein or in certificates delivered pursuant hereto shall survive, as of their
respective dates, regardless of (i) any investigation made by or on behalf of MLV, any controlling
persons, or the Company (or any of their respective officers, directors or controlling persons),
(ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination
of this Agreement.
13. Termination.
(a) MLV may terminate this Agreement, by notice to the Company, as hereinafter specified at
any time (1) if there has been, since the time of execution of this Agreement or since the date as
of which information is given in the Prospectus, any Material Adverse Effect, or any development
that has actually occurred and is reasonably expected to have a Material Adverse Effect has
occurred or in the reasonable judgment of MLV makes it impractical or inadvisable to market the
Placement Shares hereunder, (2) if there has occurred any material adverse change in the financial
markets in the United States or the international financial markets, any outbreak of hostilities or
escalation thereof or other calamity or crisis or any change or development involving a prospective
change in national or international political, financial or economic conditions, in each case the
effect of which, in the reasonable judgment of MLV, makes it impractical or inadvisable to sell the
Placement Shares hereunder, (3) if trading in the Common Shares has been suspended or limited by
the Commission or the Exchange, or if trading generally on the Exchange has been suspended or
limited, or minimum prices for trading
29
have been fixed on the Exchange, (4) if any suspension of trading of any securities of the
Company on any exchange or in the over-the-counter market shall have occurred and be continuing,
(5) if a major disruption of securities settlements or clearance services in the United States
shall have occurred and be continuing, or (6) if a banking moratorium has been declared by either
U.S. Federal or New York authorities. Any such termination shall be without liability of any party
to any other party except that the provisions of Section 9 (Expenses), Section 11
(Indemnification), Section 12 (Survival of Representations), Section 18 (Applicable
Law; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof shall remain in
full force and effect notwithstanding such termination. If MLV elects to terminate this Agreement
as provided in this Section 13(a), MLV shall provide the required notice as specified in Section 14
(Notices).
(b) (i) The Company shall have the right, by giving ten (10) days notice as hereinafter
specified to terminate this Agreement in its sole discretion at any time after the date of this
Agreement.
(ii) If MLV declines any commercially reasonable Placement Notice pursuant to clause (i) of
Section 2 of this Agreement, then the Company shall have the right to terminate this Agreement by
giving written notice of termination to MLV. Any such termination shall be effective immediately
upon a delivery of a termination notice by the Company to MLV.
Any termination pursuant to Section 13(b) shall be without liability of any party to any other
party except that the provisions of Section 9, Section 11, Section 12,
Section 18 and Section 19 hereof shall remain in full force and effect
notwithstanding such termination.
(c) MLV shall have the right, by giving ten (10) days notice as hereinafter specified to
terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any
such termination shall be without liability of any party to any other party except that the
provisions of Section 9, Section 11, Section 12, Section 18 and Section 19 hereof shall remain in
full force and effect notwithstanding such termination.
(d) Unless earlier terminated pursuant to this Section 13, this Agreement shall
automatically terminate upon the earlier to occur of (i) the two (2) year anniversary of the date
hereof or (ii) the issuance and sale of all of the Placement Shares through MLV on the terms and
subject to the conditions set forth herein, except that, in either such case, the provisions of
Section 9, Section 11, Section 12, Section 18 and Section
19 hereof shall remain in full force and effect notwithstanding such termination.
(e) This Agreement shall remain in full force and effect unless terminated pursuant to
Sections 13(a), (b), (c) or (d) above or otherwise by mutual
agreement of the parties; provided, however, that any such termination by mutual agreement shall in
all cases be deemed to provide that Section 9, Section 11, Section 12,
Section 18 and Section 19 hereof shall remain in full force and effect. Upon
termination of this Agreement, the Company shall not have any liability to MLV for any discount,
commission or other compensation with respect to any Placement Shares not otherwise sold by MLV
under this Agreement.
30
(f) Any termination of this Agreement shall be effective on the date specified in such notice
of termination; provided, however, that such termination shall not be effective until the close of
business on the date of receipt of such notice by MLV or the Company, as the case may be. If such
termination shall occur prior to the Settlement Date for any sale of Placement Shares, such
Placement Shares shall settle in accordance with the provisions of this Agreement.
(g) Subject to the additional limitations set forth in Section 9 of this Agreement, in the
event of termination of this Agreement prior to the sale of any Placement Shares, MLV shall be
entitled only to reimbursement of its out-of-pocket expenses actually incurred.
14. Notices. All notices or other communications required or permitted to be given by
any party to any other party pursuant to the terms of this Agreement shall be in writing, unless
otherwise specified, and if sent to MLV, shall be delivered to:
XxXxxxxx, Xxxxx & Vlak LLC
0000 Xxxxxx xx xxx Xxxxxxxx
00xx Xxxxx
Xxx Xxxx, XX 00000
Attention: General Counsel
Facsimile: (000) 000-0000
0000 Xxxxxx xx xxx Xxxxxxxx
00xx Xxxxx
Xxx Xxxx, XX 00000
Attention: General Counsel
Facsimile: (000) 000-0000
with a copy to:
LeClairRyan, P.C.
000 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxxx X. Xxxxx
Facsimile: (000) 000-0000
000 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxxx X. Xxxxx
Facsimile: (000) 000-0000
And if to the Company, shall be delivered to:
Aeterna Zentaris Inc.
1405 du Parc-Technologique Boulevard
Quebec City, Quebec
Canada, GIP 4P5
Attention: Xxxxxx Xxxxxx,
Chief Financial Officer
Facsimile: (000) 000-0000
1405 du Parc-Technologique Boulevard
Quebec City, Quebec
Canada, GIP 4P5
Attention: Xxxxxx Xxxxxx,
Chief Financial Officer
Facsimile: (000) 000-0000
With a copy to:
Ropes & Xxxx LLP
Prudential Tower
000 Xxxxxxxx Xxxxxx
Prudential Tower
000 Xxxxxxxx Xxxxxx
00
Xxxxxx, XX 00000-0000
Attention: Xxxxxxx X’Xxxxx, Esq.
Facsimile: (000) 000-0000
Attention: Xxxxxxx X’Xxxxx, Esq.
Facsimile: (000) 000-0000
And to:
Xxxxxx Xxxx OR LLP
0 Xxxxx Xxxxx Xxxxx, Xxxxx 0000
Xxxxxxxx, XX Xxxxxx X0X 0X0
Attention: Xxxxx Xxxxx and Xxxxxx Xxxxxxx
Facsimile: (000) 000-0000
0 Xxxxx Xxxxx Xxxxx, Xxxxx 0000
Xxxxxxxx, XX Xxxxxx X0X 0X0
Attention: Xxxxx Xxxxx and Xxxxxx Xxxxxxx
Facsimile: (000) 000-0000
Each party to this Agreement may change such address for notices by sending to the parties to
this Agreement written notice of a new address for such purpose. Each such notice or other
communication shall be deemed given (i) when delivered personally or by verifiable facsimile
transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business
Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) on the next
Business Day after timely delivery to a nationally-recognized overnight courier and (iii) on the
Business Day actually received if deposited in the U.S. mail (certified or registered mail, return
receipt requested, postage prepaid). For purposes of this Agreement, “Business Day” shall
mean any day on which the Exchange and commercial banks in the City of New York are open for
business.
An electronic communication (“Electronic Notice”) shall be deemed written notice for
purposes of this Section 14 if sent to the electronic mail address specified by the
receiving party under separate cover. Electronic Notice shall be deemed received at the time the
party sending Electronic Notice receives confirmation of receipt by the receiving party. Any party
receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a
nonelectronic form (“Nonelectronic Notice”) which shall be sent to the requesting party
within ten (10) days of receipt of the written request for Nonelectronic Notice.
15. Successors and Assigns. This Agreement shall inure to the benefit of and be
binding upon the Company and MLV and their respective successors and the affiliates, controlling
persons, partners, members, officers, directors, employees and agents referred to in Section
11 hereof. References to any of the parties contained in this Agreement shall be deemed to
include the successors and permitted assigns of such party. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective
successors and permitted assigns any rights, remedies, obligations or liabilities under or by
reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign
its rights or obligations under this Agreement without the prior written consent of the other
party.
16. Adjustments for Stock Splits. The parties acknowledge and agree that all
share-related numbers contained in this Agreement shall be adjusted to take into account any share
32
consolidation, stock split, stock dividend or similar event effected with respect to the
Placement Shares.
17. Entire Agreement; Amendment; Severability. This Agreement (including all
schedules and exhibits attached hereto and Placement Notices issued pursuant hereto), together with
the Confidential Disclosure Agreement, dated December 13, 2010, by and between the Company and MLV
(the “Confidentiality Agreement”), constitute the entire agreement of the parties with
respect to the subject matter hereof and supersede all other prior and contemporaneous agreements
and undertakings, both written and oral, among the parties hereto with regard to the subject matter
hereof. Neither this Agreement nor any term hereof may be amended except pursuant to a written
instrument executed by the Company and MLV. In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstance, is held invalid, illegal or
unenforceable as written by a court of competent jurisdiction, then such provision shall be given
full force and effect to the fullest possible extent that it is valid, legal and enforceable, and
the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or
unenforceable term or provision was not contained herein, but only to the extent that giving effect
to such provision and the remainder of the terms and provisions hereof shall be in accordance with
the intent of the parties as reflected in this Agreement.
18. GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY
AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL
BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY.
19. CONSENT TO JURISDICTION. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE
NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH
OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION
CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR
PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT
SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT,
ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS
AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY
THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN
EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD
AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING
33
CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER
PERMITTED BY LAW.
20. Use of Information. MLV may not use any information gained in connection with
this Agreement and the transactions contemplated by this Agreement, including due diligence, to
advise any party with respect to transactions not expressly approved by the Company. MLV
acknowledges that any information gained in connection with this Agreement and the transactions
contemplated by this Agreement are subject to confidentiality and other restrictions pursuant to
the Confidentiality Agreement and agrees to abide by the terms of the Confidentiality Agreement.
MLV hereby covenants and agrees that it shall not, during the term of this Agreement and for a
period of twelve (12) months thereafter, advise, counsel or in any way be associated with respect
to a matter adverse to the Company or in connection with any unsolicited or unfriendly tender offer
or take-over bid to acquire the Company or its Common Shares or any other matter potentially
involving a change in control of the Company or a change in the Board of Directors of the Company.
21. Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile
transmission.
22. Effect of Headings.
The section and Exhibit headings herein are for convenience only and shall not affect the
construction hereof.
23. Permitted Free Writing Prospectuses.
Each of the Company and MLV represents, warrants and agrees that, unless it obtains the prior
consent of the other party, it has not made and will not make any offer relating to the Placement
Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute
a “free writing prospectus,” as defined in Rule 405, required to be filed with the Commission. Any
such free writing prospectus consented to by MLV or by the Company, as the case may be, is
hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company represents and
warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus
as an “issuer free writing prospectus,” as defined in Rule 433, and has complied and will comply
with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including
timely filing with the Commission where required, legending and record keeping.
34
24. Absence of Fiduciary Relationship.
The Company acknowledges and agrees that:
(a) MLV is acting solely as agent in connection with the public offering of the Placement
Shares and in connection with each transaction contemplated by this Agreement and the process
leading to such transactions, and no fiduciary or advisory relationship between the Company or any
of its respective affiliates, stockholders (or other equityholders), creditors or employees or any
other party, on the one hand, and MLV, on the other hand, has been or will be created in respect of
any of the transactions contemplated by this Agreement, irrespective of whether or not MLV has
advised or is advising the Company on other matters, and MLV has no obligation to the Company with
respect to the transactions contemplated by this Agreement except the obligations expressly set
forth in this Agreement;
(b) it is capable of evaluating and understanding, and understands and accepts, the terms,
risks and conditions of the transactions contemplated by this Agreement;
(c) MLV has not provided any legal, accounting, regulatory or tax advice with respect to the
transactions contemplated by this Agreement and it has consulted its own legal, accounting,
regulatory and tax advisors to the extent it has deemed appropriate; and
(d) it is aware that MLV and its affiliates are engaged in a broad range of transactions which
may involve interests that differ from those of the Company and MLV has no obligation to disclose
such interests and transactions to the Company by virtue of any fiduciary, advisory or agency
relationship or otherwise; provided that MLV hereby agrees not to engage in any such transaction
which would cause its interests to be in direct conflict with the best interests of the Company.
25. Definitions.
As used in this Agreement, the following terms have the respective meanings set forth below:
“Applicable Time” means (i) each Representation Date and (ii) the time of each sale of
any Placement Shares pursuant to this Agreement.
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as
defined in Rule 433, relating to the Placement Shares.
“Rule 163,”
“Rule 164,” “Rule 172,” “Rule 405,”and “Rule
433” refer to such rules promulgated under the Securities Act.
All references in this Agreement to financial statements and schedules and other information
that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and
all other references of like import) shall be deemed to mean and include all such financial
statements and schedules and other information that is incorporated by reference in the
Registration Statement or the Prospectus, as the case may be.
35
All references in this Agreement to the Registration Statement, the Prospectus or any
amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the
Commission pursuant to XXXXX; all references in this Agreement to any Issuer Free Writing
Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not
required to be filed with the Commission) shall be deemed to include the copy thereof filed with
the Commission pursuant to XXXXX; and all references in this Agreement to “supplements” to the
Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials
prepared in connection with any offering, sale or private placement of any Placement Shares by MLV
outside of the United States to the extent those materials are reviewed and consented to in advance
by the Company.
[Signature Page Follows]
36
If the foregoing correctly sets forth the understanding between the Company and MLV, please so
indicate in the space provided below for that purpose, whereupon this letter shall constitute a
binding agreement between the Company and MLV.
Very truly yours, | ||||||
AETERNA ZENTARIS INC. | ||||||
By: | /s/ Xxxxxx Xxxxxx | |||||
Name: Xxxxxx Xxxxxx | ||||||
Title: Senior Vice-President and Chief Financial Officer |
||||||
ACCEPTED as of the date first-above written: | ||||||
XXXXXXXX, XXXXX & VLAK LLC | ||||||
By: | /s/ Xxxxxxx XxXxxxxx | |||||
Name: Xxxxxxx XxXxxxxx | ||||||
Title: Chief Executive Officer |
SCHEDULE 1
FORM OF PLACEMENT NOTICE
From:
|
Aeterna Zentaris Inc. | |
To:
|
XxXxxxxx, Xxxxx & Vlak LLC | |
Attention: Xxxxxxx XxXxxxxx | ||
Subject:
|
At Market Issuance—Placement Notice |
Gentlemen:
Pursuant to the terms and subject to the conditions contained in the At Market Issuance Sales
Agreement between Aeterna Zentaris Inc. (the “Company”), a corporation formed under the
Canada Business Corporations Act, and XxXxxxxx, Xxxxx &
Vlak LLC (“MLV”), dated June 29, 2011, the Company hereby requests that MLV sell up to ____________ of the Company’s Common
Shares, no par value per share, at a minimum market price of $_______ per share, during the time
period beginning [month, day, time] and ending [month, day, time].
SCHEDULE 2
Compensation
The Company shall pay to MLV in cash, upon each sale of Placement Shares pursuant to this
Agreement, an amount equal to 3.0% of the gross proceeds from each sale of Placement Shares.
SCHEDULE 3
Notice Parties
The Company
Xxxxxxx Xxxxx
Xxxxxx Xxxxxx
Xxxxxxxx Xxxxxx
MLV
Xxxxx Xxxxxxxxx
Xxxx Xxxxxxx
Xxxxxxx XxXxxxxx
SCHEDULE 4
Subsidiaries
Aeterna Zentaris GmbH
Zentaris IVF GmbH (a subsidiary of Aeterna Zentaris GmbH)
Aeterna Zentaris, Inc.
SCHEDULE 5
Agreements Subject to a Confidential Treatment Order
1. | License Agreement for Perifosine, by and among Aeterna Zentaris GmbH and Yakult Honsha Co, Ltd., dated as of March 8, 2011. |
2. | Purchase Agreement, by and among Aeterna Zentaris IVF GmbH, Aeterna Zentaris GmbH, Aeterna Zentaris Inc. and Xxxxx Healthcare Royalty Partners, L.P., dated as of November 11, 2008. |
3. | License and Cooperation Agreement for Perifosine, by and among Zentaris AG and AOI Pharma Inc., dated as of September 18, 2002. |
EXHIBIT 7(l)
Form of Representation Date Certificate
This Officer’s Certificate (this “Certificate”) is executed and delivered in connection
with Section 7(l) of the At Market Issuance Sales Agreement (the “Agreement”), dated
June 29, 2011, and entered into between Aeterna Zentaris Inc. (the “Company”) and
XxXxxxxx, Xxxxx & Vlak LLC. All capitalized terms used but not defined herein shall have the
meanings given to such terms in the Agreement.
The undersigned has carefully examined the Registration Statement, the Prospectus, any supplements
to the Prospectus (each as defined in the Agreement) and the Agreement and hereby certifies that:
1. the representations and warranties of the Company in the Agreement are true and correct in all
material respects on and as of the date hereof and the Company has complied with all the agreements
and satisfied all the conditions on its part to be performed or satisfied at or prior to the date
hereof;
2. to the Company’s knowledge, no stop order suspending the effectiveness of the Registration
Statement has been issued and no proceedings for that purpose have been instituted or threatened;
and
3. since the date of the most recent financial statements included in the Prospectus (exclusive of
any supplement thereto subsequent to the date hereof), there has been no event or condition
constituting a Material Adverse Effect, except as set forth in or contemplated in the Prospectus
(exclusive of any supplement thereto subsequent to the date hereof).
AETERNA ZENTARIS INC. | ||||||
By: | ||||||
Name: | ||||||
Title: | ||||||
43